Ralph Brinks

Ralph Brinks

Auto-generated profile, based on publicly available information

Ralph Brinks

Chair for Medical Biometry and Epidemiology Faculty of Health/School of Medicine Witten/Herdecke University D-58448 Witten Germany

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2013 in Rheumatology
Verified
Journal Article
Closed access
PDF file
RFRebecca Fischer-Betz
Rebecca Fischer-Betz
CSChristof Specker
Christof Specker
RBRalph Brinks
Ralph Brinks
MAMartin Aringer
Martin Aringer
MSMatthias Schneider
Matthias Schneider
Objective. MMF is teratogenic and needs to be replaced before pregnancy. This change may lead to flares. Our aim was to determine the risk of renal flares in women with LN who switched treatment from MMF to AZA before conception and to evaluate the outcome of their pregnancies.

1 March 2014 in Theoretical Population Biology
Verified
Journal Article
Closed access
RBRalph Brinks
Ralph Brinks
SLSandra Landwehr
Sandra Landwehr

9 January 2015 in Mathematical Medicine and Biology: A Journal of the IMA
Verified
Journal Article
Open access
PDF file
RBRalph Brinks
Ralph Brinks
SLSandra Landwehr
Sandra Landwehr
In 1991 Keiding published a relation between the age-specific prevalence and incidence of a chronic disease (in Age-specific incidence and prevalence: a statistical perspective. J. Roy. Stat. Soc. A, 154, 371–412). For special cases alternative formulations by differential equations were given recently in Brinks et al. (2013, Deriving age-specific incidence from prevalence with an ordinary differential equation. Statist. Med., 32, 2070–2078) and in Brinks & Landwehr (2014, Age- and time-dependent model of the prevalence of non-communicable diseases and application to dementia in Germany, Theor. Popul. Biol., 92, 62–68). From these works, we generalize formulations and discuss the advantages of the novel approach. As an implication, we obtain a new way of estimating the incidence rate of a chronic disease from prevalence data. This enables us to employ cross-sectional studies where otherwise expensive and lengthy follow-up studies are needed. This article illustrates and validates the novel method in a simulation study about dementia in Germany.

13 June 2014 in Lupus
Verified
Journal Article
Closed access
RBR Brinks
R Brinks
RFR Fischer-Betz
R Fischer-Betz
OSOliver Sander
Oliver Sander
JRJ G Richter
J G Richter
GCG Chehab
G Chehab
MSM Schneider
M Schneider
Objective: The objective of this report is to estimate the prevalence and future number of cases of systemic lupus erythematosus (SLE) in Germany. Methods: Data from a representative sample of all insurants from the statutory health insurance in Germany comprising more than 2.3 million individuals have been screened for SLE diagnoses. The gender- and age-specific prevalence of SLE is calculated. The case definition is based on at least one recorded diagnosis of SLE during 2002. The stratum-specific prevalence is applied to the current and the future population of Germany in order to estimate and predict the number of people with SLE until 2030. Results: The overall prevalence of diagnosed SLE in 2002 was 15.4 (95% CI: 13.1–17.9) and 55.4 (51.4, 59.8) per 100,000 in the male and female German population. This corresponds to an estimated 30,000 and 31,000 people with diagnosed SLE in 2002 and 2010, respectively. This number will slightly increase until 2020 and decrease thereafter. Conclusions: Compared with health insurance data from France, the prevalence in our data is similar. Under the assumption that the gender- and age-specific prevalence of SLE in Germany will not change considerably, the number of cases in the next two decades will change only slightly.

8 June 2012 in Lupus
Verified
Journal Article
Closed access
PDF file
RFR Fischer-Betz
R Fischer-Betz
CSC Specker
C Specker
RBR Brinks
R Brinks
MSM Schneider
M Schneider
Among the most prominent features associated with antiphospholipid syndrome (APS) are cerebral ischaemic events (CVE). Pregnancy with APS increases the risk of thrombosis, including CVE. This study was undertaken to assess the risk of obstetric complications and recurrence of CVE during pregnancy in women with APS and previous CVE. We prospectively observed 23 pregnancies in 20 women (median age 31 years) with primary (n = 8) or secondary APS (n = 12). Eight patients had transient ischaemic attacks (TIA) and 12 had stroke before pregnancy. All patients received aspirin 100 mg daily in combination with low molecular weight heparin (LMWH) during their pregnancies. The live birth rate was 91.3% (n = 21). Obstetrical complications consisted mainly of preeclampsia (n = 8, 34.8%) and preterm delivery (n = 9, 42.9%). The risk for preeclampsia increased in patients who were positive for multiple antiphospholipid antibodies (aPL) (odds ratio (OR) 3.06 (95% confidence interval (CI) 1.01–9.32)) per positive aPL test (i.e anticardiolipin antibody, anti-ß2-glycoprotein I antibody, lupus anticoagulant) (p 0.049). Three patients experienced recurrent CVE in the context of pregnancy (one during pregnancy, two in the postpartum period). We found an increased, but not significant, risk of a new episode of cerebral ischaemia in patients with pregnancies complicated by preeclampsia (two out of the eight preeclampsia (p 0.15). Despite treatment, there is a significant risk for pregnancy complications in APS patients with previous CVE. Especially in the context of preeclampsia, anticoagulation should be given rigorously to prevent recurrence of CVE.

18 March 2013 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
RWR. Waldeyer
R. Waldeyer
RBR. Brinks
R. Brinks
WRW. Rathmann
W. Rathmann
GGG. Giani
G. Giani
AIA. Icks
A. Icks